Bo Lan-Jun, Liang Ai-Bin, Liu Ban, Chen Yu-Hua, Wang Fei, Jin Xue-Ping
Department of Hematology, Tongji Hospital, Tongji University, Shanghai, 200065, P. R. China.
Ai Zheng. 2006 Dec;25(12):1553-6.
BACKGROUND & OBJECTIVE: There is no standard salvage regimen for patients with recurrent and refractory non-Hodgkin's lymphoma (NHL) so far. This study was to investigate the efficacy of DICE (dexamethasone, isofosfamide, cisplatin, and etoposide) regimen on recurrent and refractory NHL, and observe the adverse events.
Clinical records of 80 patients with recurrent and refractory NHL, who failed to get remission from CHOP regimen (cyclophosfamide, vincristine, and donaurubicin) and accepted DICE as a salvage regimen for 6 cycles, were reviewed. Of the 80 patients, 25 were T-cell original, and the other 55 were B-cell original. The efficacy of DICE regimen and adverse events were evaluated.
The total response rate (RR) of these 80 patients was 56.3%. The complete remission (CR) rate was 27.5%.The total response rate was 48.0% for T-cell NHL and 60.0% for B-cell NHL. The CR rate was 16.0% for T-cell NHL and 32.7% for B-cell NHL. Myelosuppression, nausea, vomit, alopecia, and electrolytes disorder were major adverse events, and could be cured after treatment. No chemotherapy-related death occurred.
DICE regimen is effective in treating recurrent and refractory NHL.
目前对于复发难治性非霍奇金淋巴瘤（NHL）患者尚无标准挽救方案。本研究旨在探讨地塞米松、异环磷酰胺、顺铂和依托泊苷（DICE）方案治疗复发难治性NHL的疗效，并观察不良反应。
回顾性分析80例复发难治性NHL患者的临床资料，这些患者接受CHOP方案（环磷酰胺、长春新碱和多柔比星）治疗未缓解，接受DICE方案作为挽救方案化疗6个周期。80例患者中，25例为T细胞来源，55例为B细胞来源。评估DICE方案的疗效及不良反应。
80例患者的总缓解率（RR）为56.3%，完全缓解（CR）率为27.5%。T细胞NHL的总缓解率为48.0%，B细胞NHL为60.0%；T细胞NHL的CR率为16.0%，B细胞NHL为32.7%。主要不良反应为骨髓抑制、恶心、呕吐、脱发和电解质紊乱，治疗后可治愈。无化疗相关死亡发生。
DICE方案治疗复发难治性NHL有效。
